isabelobrien, Author at European Medical Journal - Page 5 of 29

Kennedy secures US health role despite backlash

Robert F. Kennedy Jr has been confirmed as the US Secretary of Health and Human Services following a 52-48 Senate vote.

5 minutes with... Jaime Manzanera, Eisai

Jaime Manzanera, EMEA Brand Director, Oncology, Eisai, shares his perspective on maximising ROI in pharmaceutical marketing and more.

Handshake on a green background

Novartis to acquire Anthos Therapeutics for $925m

To boost its cardiovascular pipeline, Novartis has announced the acquisition of the company it co-founded with Blackstone Life Sciences.

Lupus nephritis drug delivers promising results, says Roche

Obinutuzumab could reshape the treatment of lupus nephritis, a life-threatening complication of lupus that has long lacked effective options.

First and only chikungunya vaccine approved in UK

The world’s first chikungunya vaccine, developed by French pharmaceutical firm Valneva SE, has been approved in the UK by the MHRA.

J&J’s Martin Price on World Cancer Day 2025 – Part 1

A World Cancer Day edition of the podcast, with Martin Price, Vice President, Health Economics, Market Access and Reimbursement, EMEA, J&J.

The world

US funding pause potential threat to global HIV efforts, warns WHO

The World Health Organization has responded to the US government’s freezing of HIV funding as part of a broader pause in foreign aid.

The word spotlight on a blue background

Spotlight: January 2025

Catch up on January’s top pharma news, from major industry deals and cutting-edge medical innovations to advancements in women’s health.

GSK and Oxford unite to advance cancer vaccine research

The new collaboration between GSK and the Univeristy of Oxford aims to explore cancer prevention through vaccination.

The 2025 pharma forecast

Curious to know could happen in the industry in 2025? Join us as we talk to three guests about their top predictions for the year ahead.